As reported by Technology, a major evidence synthesis published in The BMJ has delivered the clearest picture to date of which therapies offer the strongest short‑term benefits for people with attention deficit hyperactivity disorder (ADHD). The umbrella review—the largest of its kind—concludes that medication remains the most reliable treatment for children, adolescents, and adults, while cognitive behavioural therapy (CBT) stands out as particularly effective for adults.
Largest Assessment of ADHD Treatments Conducted to Date
The international research team, led by investigators from Université Paris Nanterre, Institut Robert-Debré du Cerveau de l’Enfant, and the University of Southampton, evaluated more than 200 meta-analyses spanning pharmacologic, psychological, and complementary approaches. Public research agencies in France and the United Kingdom supported the work.
To help clinicians and patients navigate the crowded and often confusing treatment landscape, the researchers also launched a freely accessible decision-support website (ebiadhd-database.org). The platform summarizes the strength of evidence behind each intervention and is updated as new data emerge.
Clear Short‑Term Benefits—but a Gap in Long‑Term Evidence
Across the analyses, five medications showed meaningful therapeutic impact for young people with ADHD. Adults benefited from two medications as well as CBT, which demonstrated consistently positive outcomes in the short term. Notably, most available research does not extend beyond short‑duration trials, leaving an important evidence gap given how frequently long‑term treatment is used in clinical practice.
Some non-pharmacological options—such as mindfulness, exercise, and acupuncture—showed early signs of promise. However, the authors classified the supporting evidence as low quality due to small study sizes or methodological limitations. Mindfulness stood out as the only intervention associated with substantial benefits at longer follow-up, though more rigorous research is needed.
Supporting Shared Decision‑Making
The researchers emphasize that misinformation and long wait times for services can complicate treatment decisions for individuals seeking ADHD care. By presenting a consolidated view of the evidence, the team hopes their database will streamline discussions between patients and clinicians and help reduce time spent pursuing ineffective strategies.
Implications for Guidelines and Clinical Practice
The review aligns with many existing international guidelines while filling important gaps—particularly for interventions not routinely evaluated in official recommendations. The authors anticipate the new resource will influence clinical practice in the same way their prior evidence platform has shaped autism treatment guidance.
The full study, Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making, is available in The BMJ.
